Wockhardt (WOCKPHARMA) Share Price Falls 2.23% as Stock News Tracks Rs 2,277.85
- September 24, 2026
- Posted by: Harsh Piplani
- Category: News
Wockhardt Share Price fell today, with the stock closing at Rs 2,277.85 after a decline of 2.23%. The move is visible in Wockhardt Share Price Today because the stock was down Rs 51.95 from the previous close of Rs 2,329.80. With a market capitalisation of Rs 35,503.73 crore, the company sits in the Large Cap category, which gives the decline meaningful index and portfolio relevance even without a company-specific trigger in the supplied data.
The session opened at Rs 2,307.95, touched a high of Rs 2,333.00 and a low of Rs 2,276.35. Turnover stood at Rs 14.37 crore. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For readers tracking Wockhardt Stock News, the key question is not only why the share price fell today, but also how this move fits into valuation, sector context and the company’s published financial profile. Univest is using the verified figures below to place the move in a broader stock analysis frame.
Wockhardt (WOCKPHARMA) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,277.85 |
| Previous Close | Rs 2,329.8 |
| Today's Move | -Rs 51.95 (-2.23%) |
| Open | Rs 2,307.95 |
| High | Rs 2,333 |
| Low | Rs 2,276.35 |
| Turnover | Rs 14.37 crore |
| Market Capitalisation | Rs 35,503.73 crore |
| Market Cap Category | Large Cap |
Wockhardt Share Price Today reflected a clear intraday decline rather than a flat session. The stock opened at Rs 2,307.95, moved to Rs 2,333.00 at the day’s high and Rs 2,276.35 at the day’s low before settling at Rs 2,277.85. Against the previous close of Rs 2,329.80, the day change was Rs -51.95, or -2.23%. That makes today’s decline easy to quantify without adding any unsupported explanation. The price stayed close to the lower end of the session range by the close, which is relevant for readers following Wockhardt Share Price Live and Wockhardt Share Price Update coverage.
Turnover was Rs 14.37 crore, and the stock remains classified as Large Cap in the supplied market-cap category. That company-size context matters for Wockhardt Stock News because the same percentage move in a larger company can carry different headline impact than in a smaller one, yet the data here does not support any further cause-based interpretation. The facts point to a day of weakness in share price terms, with the stock finishing below the previous close and below the opening level. For investors scanning Wockhardt Share Price Today, the next layer of analysis is whether the valuation and financial metrics justify the current price band.
Wockhardt (WOCKPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 35,503.73 crore |
| P/E Ratio | 92.56x |
| P/B Ratio | 7.52x |
| ROE | 4.29% |
| ROCE | 6.79% |
| EPS | Rs 25.17 |
| Book Value Per Share | Rs 309.81 |
| Dividend Yield | 0% |
Profitability metrics are modest in the supplied data: ROE stands at 4.29% and ROCE at 6.79%. In a stock analysis framework, those figures matter because they help explain how much operating and shareholder return is visible in the reported metrics. Univest readers tracking Wockhardt Fundamental Analysis should also note that the current price of Rs 2,277.85 sits far above the book value per share, while the high P/E and P/B need to be read alongside the company’s reported earnings base. Wockhardt Share Price therefore remains a valuation-sensitive name in the current snapshot, and that is the main fundamental context investors can verify from the supplied numbers.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 92.56x |
| Benchmark Median P/E | 31.9x |
| Benchmark Average P/E | 50.01x |
| Benchmark P/E Range | 3.48x to 762.66x |
| Company P/B Ratio | 7.52x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.38x |
| Company ROE | 4.29% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.65% |
| Company ROCE | 6.79% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.26% |
| Company Market Capitalisation | Rs 35,503.73 crore |
| Benchmark Median Market Cap | Rs 761.61 crore |
| Benchmark Average Market Cap | Rs 14,299.75 crore |
Wockhardt operates in Healthcare within the Pharmaceuticals & Drugs industry, and the supplied benchmark covers the same industry with 200 companies. In that benchmark, the company’s P/E of 92.56 compares with a median of 31.90 and an average of 50.01. Its P/B of 7.52 compares with a median of 3.00 and an average of 4.38. On profitability, ROE at 4.29% is below the industry median of 11.70% and average of 10.65%, while ROCE at 6.79% is also below the industry median of 13.46% and average of 13.26%.
The sector data also shows the company’s market capitalisation of Rs 35,503.73 crore versus an industry median of Rs 761.61 crore and an average of Rs 14,299.75 crore across the same-industry sample. That places Wockhardt well above the median and above the average on size. In sector analysis terms, Wockhardt Share Price is therefore being assessed against a wide healthcare universe where peer valuation and return metrics vary sharply. The stock’s pricing is richer than the benchmark median on both P/E and P/B, while its return ratios sit below the benchmark medians. That is the main sector context for Wockhardt Share Price Today and for readers comparing Wockhardt Stock News with the wider pharmaceutical space.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,42,437.37 | 37 | 5.17 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,48,053.84 | 87.1 | 14.42 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,841.6 | 86.85 | 21.1 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,810.19 | 25.85 | 4.33 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,565.25 | 33.08 | 3.17 | 11.83 | 16 |
Peer comparison helps position Wockhardt Share Price against other listed healthcare names in the same industry. Wockhardt’s P/E of 92.56 is above Sun Pharmaceutical Industries at 37.00, Zydus Lifesciences at 25.85, Cipla at 33.08 and Dr. Reddy’s Laboratories at 31.35, while it is slightly below Divi’s Laboratories at 87.10 only by a modest margin? No—the supplied numbers show Wockhardt is still above Divi’s Laboratories as well. That makes Wockhardt one of the richer-valued names in the peer set on earnings multiples.
On returns, Wockhardt’s ROE of 4.29% and ROCE of 6.79% sit below each of the supplied peers in this comparison set, including Sun Pharmaceutical, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences, Cipla, Laurus Labs, Mankind Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma and Lupin. Its market capitalisation of Rs 35,503.73 crore is smaller than Sun Pharmaceutical, Divi’s Laboratories, Torrent Pharmaceuticals and several other peers, but larger than some mid-tier names in the group. For Wockhardt Share Price, the peer takeaway is straightforward: valuation is high relative to the supplied peer sample, while returns are lower than the companies listed here.
Why Investors Are Watching Wockhardt
- Wockhardt Share Price fell 2.23% today to Rs 2,277.85 from the previous close of Rs 2,329.80.
- The day’s open was Rs 2,307.95, the high was Rs 2,333.00 and the low was Rs 2,276.35.
- Market capitalisation stands at Rs 35,503.73 crore and the market-cap category is Large Cap.
- The stock trades at a P/E of 92.56 and a P/B of 7.52, with EPS of Rs 25.17 and book value of Rs 309.81.
- ROE is 4.29% and ROCE is 6.79%, both below the supplied industry benchmark medians.
About Wockhardt
Wockhardt operates in Healthcare and is classified in the Pharmaceuticals & Drugs industry. The supplied data does not extend into product-wise or segment-wise detail, so the company profile here stays to the verified sector and industry classification. For Wockhardt Share Price readers, that means the key factual backdrop is the company’s location within a broad pharmaceutical universe rather than a deeper business-description narrative. Wockhardt Stock News therefore needs to be read in the context of the share price move, market capitalisation, valuation ratios and return metrics already outlined above.
Track Wockhardt Share Price on Univest
Use Wockhardt (WOCKPHARMA) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track Wockhardt Share Price on Univest for live share price updates, stock analysis, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest also organises Wockhardt Share Price Today data into a clear research view so investors can compare price action, valuation and sector context in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Wockhardt Share Price Today?
Ans. Wockhardt Share Price Today is Rs 2,277.85. The stock declined from the previous close of Rs 2,329.80, with the session opening at Rs 2,307.95 and the low at Rs 2,276.35.
What is Wockhardt’s market capitalisation?
Ans. Wockhardt’s market capitalisation is Rs 35,503.73 crore. The company is also classified as Large Cap in the supplied data, which gives the day’s decline important size context. The company operates in the Healthcare sector.
How do Wockhardt’s valuation metrics look?
Ans. Wockhardt trades at a P/E of 92.56 and a P/B of 7.52. EPS is Rs 25.17 and book value is Rs 309.81, while dividend yield is 0 in the supplied snapshot.
How does Wockhardt compare with healthcare peers?
Ans. Wockhardt’s P/E is above several healthcare peers in the supplied list, and its ROE and ROCE are below the peer sample shown. That creates a clear valuation-versus-return contrast in Wockhardt Share Price analysis.
What should investors monitor next in Wockhardt Share Price?
Ans. Investors can monitor whether Wockhardt Share Price stabilises around today’s close, how valuation metrics compare with the healthcare benchmark, and whether future published company data changes the current fundamental picture.
